Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

ChromaDex

Nasdaq:CDXC
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CDXC
Nasdaq
$210M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

ChromaDex Corporation operates as a nutraceutical company. The last earnings update was 28 days ago. More info.


Add to Portfolio Compare Print
  • ChromaDex has significant price volatility in the past 3 months.
CDXC Share Price and Events
7 Day Returns
8%
NasdaqCM:CDXC
-1.7%
US Life Sciences
-2.6%
US Market
1 Year Returns
-17.6%
NasdaqCM:CDXC
-7.3%
US Life Sciences
-13.3%
US Market
CDXC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ChromaDex (CDXC) 8% -2% -26.3% -17.6% 42.3% -12.9%
US Life Sciences -1.7% -10.5% -17.3% -7.3% 59.6% 80.6%
US Market -2.6% -15.2% -22.2% -13.3% 5.7% 17.2%
1 Year Return vs Industry and Market
  • CDXC underperformed the Life Sciences industry which returned -7.3% over the past year.
  • CDXC underperformed the Market in United States of America which returned -13.3% over the past year.
Price Volatility
CDXC
Industry
5yr Volatility vs Market

CDXC Value

 Is ChromaDex undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ChromaDex to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ChromaDex.

NasdaqCM:CDXC Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 1.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:CDXC
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 1.7%
Equity Risk Premium S&P Global 5.4%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.03
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.029 (1 + (1- 21%) (0.82%))
1.024
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.02
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.74% + (1.024 * 5.44%)
7.31%

Discounted Cash Flow Calculation for NasdaqCM:CDXC using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ChromaDex is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqCM:CDXC DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.31%)
2020 -16.80 Analyst x2 -15.65
2021 5.18 Analyst x3 4.50
2022 17.02 Analyst x2 13.78
2023 27.98 Est @ 64.36% 21.10
2024 40.73 Est @ 45.57% 28.62
2025 53.94 Est @ 32.42% 35.32
2026 66.46 Est @ 23.22% 40.56
2027 77.61 Est @ 16.78% 44.14
2028 87.13 Est @ 12.26% 46.18
2029 95.06 Est @ 9.11% 46.95
Present value of next 10 years cash flows $265.00
NasdaqCM:CDXC DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $95.06 × (1 + 1.74%) ÷ (7.31% – 1.74%)
$1,736.51
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,736.51 ÷ (1 + 7.31%)10
$857.60
NasdaqCM:CDXC Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $265.00 + $857.60
$1,122.60
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,122.60 / 59.97
$18.72
NasdaqCM:CDXC Discount to Share Price
Calculation Result
Value per share (USD) From above. $18.72
Current discount Discount to share price of $3.50
= -1 x ($3.50 - $18.72) / $18.72
81.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price ChromaDex is available for.
Intrinsic value
>50%
Share price is $3.5 vs Future cash flow value of $18.72
Current Discount Checks
For ChromaDex to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • ChromaDex's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • ChromaDex's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ChromaDex's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ChromaDex's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:CDXC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.56
NasdaqCM:CDXC Share Price ** NasdaqCM (2020-04-06) in USD $3.5
United States of America Life Sciences Industry PE Ratio Median Figure of 19 Publicly-Listed Life Sciences Companies 28.76x
United States of America Market PE Ratio Median Figure of 2,946 Publicly-Listed Companies 12.49x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ChromaDex.

NasdaqCM:CDXC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CDXC Share Price ÷ EPS (both in USD)

= 3.5 ÷ -0.56

-6.21x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ChromaDex is loss making, we can't compare its value to the US Life Sciences industry average.
  • ChromaDex is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does ChromaDex's expected growth come at a high price?
Raw Data
NasdaqCM:CDXC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.21x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
92.2%per year
United States of America Life Sciences Industry PEG Ratio Median Figure of 16 Publicly-Listed Life Sciences Companies 2.21x
United States of America Market PEG Ratio Median Figure of 2,010 Publicly-Listed Companies 0.89x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ChromaDex, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ChromaDex's assets?
Raw Data
NasdaqCM:CDXC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.34
NasdaqCM:CDXC Share Price * NasdaqCM (2020-04-06) in USD $3.5
United States of America Life Sciences Industry PB Ratio Median Figure of 38 Publicly-Listed Life Sciences Companies 4.24x
United States of America Market PB Ratio Median Figure of 5,158 Publicly-Listed Companies 1.22x
NasdaqCM:CDXC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CDXC Share Price ÷ Book Value per Share (both in USD)

= 3.5 ÷ 0.34

10.23x

* Primary Listing of ChromaDex.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ChromaDex is overvalued based on assets compared to the US Life Sciences industry average.
X
Value checks
We assess ChromaDex's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. ChromaDex has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CDXC Future Performance

 How is ChromaDex expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
92.2%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ChromaDex expected to grow at an attractive rate?
  • ChromaDex's earnings growth is expected to exceed the low risk savings rate of 1.7%.
Growth vs Market Checks
  • ChromaDex's earnings growth is expected to exceed the United States of America market average.
  • ChromaDex's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:CDXC Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:CDXC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 92.2%
NasdaqCM:CDXC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 32.1%
United States of America Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 17.5%
United States of America Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 6.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:CDXC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:CDXC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2022-12-31 128 18 29 3
2021-12-31 90 7 5 5
2020-12-31 64 -17 -23 5
2020-04-07
NasdaqCM:CDXC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 46 -20 -32
2019-09-30 42 -25 -32
2019-06-30 38 -22 -33
2019-03-31 35 -20 -33
2018-12-31 32 -21 -33
2018-09-30 30 -20 -34
2018-06-30 28 -15 -29
2018-03-31 24 -14 -23
2017-12-30 21 -10 -17
2017-09-30 18 -6 -10
2017-07-01 16 -6 -8
2017-04-01 18 0 -6

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ChromaDex's earnings are expected to grow significantly at over 20% yearly.
  • ChromaDex's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:CDXC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from ChromaDex Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CDXC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2022-12-31 0.46 0.48 0.43 2.00
2021-12-31 0.08 0.19 0.01 3.00
2020-12-31 -0.38 -0.30 -0.51 4.00
2020-04-07
NasdaqCM:CDXC Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.56
2019-09-30 -0.56
2019-06-30 -0.60
2019-03-31 -0.60
2018-12-31 -0.61
2018-09-30 -0.63
2018-06-30 -0.55
2018-03-31 -0.47
2017-12-30 -0.37
2017-09-30 -0.24
2017-07-01 -0.19
2017-04-01 -0.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ChromaDex will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess ChromaDex's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ChromaDex has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CDXC Past Performance

  How has ChromaDex performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ChromaDex's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ChromaDex does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare ChromaDex's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ChromaDex's 1-year growth to the US Life Sciences industry average as it is not currently profitable.
Earnings and Revenue History
ChromaDex's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ChromaDex Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CDXC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 46.29 -32.15 52.52 4.42
2019-09-30 42.27 -31.51 48.94 4.56
2019-06-30 38.34 -32.92 47.95 4.86
2019-03-31 35.04 -33.21 46.08 5.21
2018-12-31 31.56 -33.32 43.67 5.48
2018-09-30 30.02 -33.92 43.23 5.66
2018-06-30 27.99 -28.54 36.68 5.35
2018-03-31 24.40 -23.17 29.47 4.78
2017-12-30 21.20 -16.53 22.10 4.01
2017-09-30 18.12 -9.89 14.49 3.09
2017-07-01 15.98 -7.60 11.45 2.82
2017-04-01 17.70 -5.61 10.87 2.72
2016-12-31 21.66 -3.55 10.67 2.52
2016-10-01 21.58 -2.79 9.56 2.40
2016-07-02 23.93 -1.87 9.66 1.81
2016-04-02 24.09 -1.49 9.56 1.23
2016-01-02 17.88 -2.64 8.71 0.89
2015-10-03 21.89 -2.57 9.17 1.00
2015-07-04 19.75 -3.23 9.22 0.81
2015-04-04 17.50 -4.57 9.78 0.63
2015-01-03 15.31 -5.39 10.00 0.51
2014-09-27 13.47 -4.89 9.68
2014-06-28 12.05 -5.48 9.47
2014-03-29 10.90 -4.84 8.40
2013-12-28 10.16 -4.42 7.34 0.13
2013-09-28 11.28 -5.39 8.58
2013-06-29 12.20 -5.68 9.40

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ChromaDex has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ChromaDex has efficiently used its assets last year compared to the US Life Sciences industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ChromaDex improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ChromaDex's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ChromaDex has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CDXC Health

 How is ChromaDex's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ChromaDex's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ChromaDex is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ChromaDex's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ChromaDex's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.5095165231021E+17x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ChromaDex Company Filings, last reported 3 months ago.

NasdaqCM:CDXC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 20.45 0.00 18.61
2019-09-30 27.14 0.00 18.68
2019-06-30 15.15 9.99 19.56
2019-03-31 20.98 0.00 19.13
2018-12-31 27.18 0.00 22.42
2018-09-30 33.40 0.00 28.21
2018-06-30 40.50 0.00 33.39
2018-03-31 46.66 0.00 41.04
2017-12-30 53.83 0.00 45.39
2017-09-30 33.74 0.00 24.00
2017-07-01 25.72 0.00 14.14
2017-04-01 9.37 0.00 1.19
2016-12-31 9.97 0.00 1.64
2016-10-01 11.86 0.00 2.26
2016-07-02 12.45 0.00 3.37
2016-04-02 6.43 4.78 3.00
2016-01-02 5.27 4.87 5.55
2015-10-03 4.34 4.83 4.71
2015-07-04 3.90 4.78 5.70
2015-04-04 3.69 2.25 3.22
2015-01-03 4.00 2.20 3.96
2014-09-27 4.50 0.00 1.20
2014-06-28 4.32 0.00 1.28
2014-03-29 4.79 0.00 1.92
2013-12-28 5.67 0.00 2.26
2013-09-28 3.27 0.00 1.09
2013-06-29 4.27 0.00 0.83
  • ChromaDex's level of debt (0%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (53.8% vs 0% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ChromaDex has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if ChromaDex has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess ChromaDex's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ChromaDex has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CDXC Dividends

 What is ChromaDex's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ChromaDex dividends.
If you bought $2,000 of ChromaDex shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ChromaDex's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ChromaDex's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:CDXC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
United States of America Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 0.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1935 Stocks 3%
United States of America Minimum Threshold Dividend Yield 10th Percentile 1.1%
United States of America Bottom 25% Dividend Yield 25th Percentile 2%
United States of America Top 25% Dividend Yield 75th Percentile 5.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:CDXC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2022-12-31
2021-12-31
2020-12-31
2020-04-07

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ChromaDex has not reported any payouts.
  • Unable to verify if ChromaDex's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ChromaDex's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ChromaDex has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ChromaDex's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ChromaDex afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ChromaDex has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CDXC Management

 What is the CEO of ChromaDex's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rob Fried
COMPENSATION $5,160,444
AGE 59
TENURE AS CEO 1.8 years
CEO Bio

Mr. Robert N. Fried, also known as Rob, has been the Chief Executive Officer of ChromaDex Corp. since June 22, 2018 and its a Director since July 2015. Mr. Fried was the Chief Operating Officer of ChromaDex Corp. since January 8, 2018 until June 22, 2018 and its President since March 2017 until June 22, 2018. Mr. Fried served as Chief Strategy Officer of ChromaDex Corp. from March 2017 to March 2018. Mr. Fried served as Chairman of the Board of Directors of IDI, Inc. (formerly Tiger Media, Inc.) from 2011 to June 2015. From 2007 to 2009, he was the President, Chief Executive Officer and a director of Ideation Acquisition Corporation, a special purpose acquisition company. Mr. Fried is the Founder and Chief Executive Officer of Feeln, a subscription streaming video service, which was acquired by Hallmark Cards Inc. in 2012. Since then, Mr. Fried manages digital businesses for Hallmark including Feeln, Hallmark e-cards, and Hallmark Print on Demand. Mr. Fried is also an Academy Award winning motion picture producer whose credits include Rudy, Collateral, Boondock Saints, So I Married an Axe Murderer, Godzilla, and numerous others. From December 1994 to June 1996, he was President and Chief Executive Officer of Savoy Pictures, a unit of Savoy Pictures Entertainment, Inc., which was sold in 1996 to Silver King Communications, which is a part of InterActive Corp. Mr. Fried has also held several executive positions including Executive Vice President in charge of Production for Columbia Pictures, Director of Film Finance and Special Projects for Columbia Pictures, and Director of Business Development at Twentieth Century Fox. He served as a Director of Cogint, Inc.( also known as Fluent, Inc.) from October 2009 to March 26, 2018 and served as its Chairman. Mr. Fried holds an M.S. from Cornell University and an M.B.A. from the Columbia University Graduate School of Business. As previously disclosed, Mr. Fried is a party to his Executive Employment Agreement, dated March 12, 2017, as amended on December 20, 2017, and the Company’s standard indemnification agreement for directors and executive officers.

CEO Compensation
  • Rob's compensation has increased whilst company is loss making.
  • Rob's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the ChromaDex management team in years:

1.8
Average Tenure
60
Average Age
  • The average tenure for the ChromaDex management team is less than 2 years, this suggests a new team.
Management Team

Rob Fried

TITLE
CEO & Director
COMPENSATION
$5M
AGE
59
TENURE
1.8 yrs

Mark Friedman

TITLE
General Counsel & Corporate Secretary
COMPENSATION
$2M
AGE
61
TENURE
2.3 yrs

Frank Jaksch

TITLE
Co-Founder & Executive Chairman
COMPENSATION
$454K
AGE
51
TENURE
21.3 yrs

Kevin Farr

TITLE
Chief Financial Officer
COMPENSATION
$3M
AGE
61
TENURE
2.5 yrs

Ben Shichman

TITLE
Chief Technology Officer
TENURE
2 yrs

Andrew Shao

TITLE
Senior Vice President of Global Regulatory & Scientific Affairs
TENURE
0.2 yrs

Brianna Gerber

TITLE
Senior Director of FP&A and Investor Relations

Megan Jordan

TITLE
Chief Communications Officer & Senior VP of Global Marketing
TENURE
0.7 yrs

Alberto Bottene

TITLE
Senior Vice President of Sales & Business Development
TENURE
0.7 yrs

Will Black

TITLE
Consultant
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the ChromaDex board of directors in years:

4.9
Average Tenure
59
Average Age
  • The tenure for the ChromaDex board of directors is about average.
Board of Directors

Frank Jaksch

TITLE
Co-Founder & Executive Chairman
COMPENSATION
$454K
AGE
51
TENURE
1.8 yrs

Stephen Block

TITLE
Non-Executive Director
COMPENSATION
$106K
AGE
74
TENURE
12.5 yrs

Rob Fried

TITLE
CEO & Director
COMPENSATION
$5M
AGE
59
TENURE
4.8 yrs

Roger Kornberg

TITLE
Chairman of the Scientific Advisory Board
AGE
72
TENURE
5.8 yrs

Kurt Gustafson

TITLE
Lead Independent Director
COMPENSATION
$125K
AGE
51
TENURE
1.8 yrs

Steve Rubin

TITLE
Independent Director
COMPENSATION
$90K
AGE
59
TENURE
3.1 yrs

Charles Brenner

TITLE
Member of Scientific Advisory Board
TENURE
5.6 yrs

J. German

TITLE
Member of Scientific Advisory Board
TENURE
5.6 yrs

Jeff Baxter

TITLE
Non-Executive Director
COMPENSATION
$96K
AGE
58
TENURE
5 yrs

Rudy Tanzi

TITLE
Member of Scientific Advisory Board
TENURE
2.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
15. Nov 19 Buy Robert Fried Individual 14. Nov 19 14. Nov 19 10,000 $3.09 $30,900
26. Aug 19 Buy Robert Fried Individual 23. Aug 19 23. Aug 19 2,500 $4.03 $10,075
22. May 19 Buy Robert Fried Individual 21. May 19 21. May 19 2,253 $4.43 $9,981
X
Management checks
We assess ChromaDex's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ChromaDex has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CDXC News

Simply Wall St News

How Much Of ChromaDex Corporation (NASDAQ:CDXC) Do Insiders Own?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … ChromaDex is a smaller company with a market capitalization of US$213m, so it may still be flying under the radar of many institutional investors. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Should You Investigate ChromaDex Corporation (NASDAQ:CDXC) At US$3.97?

As a small cap stock, which tends to lack high analyst coverage, there is generally more of an opportunity for mispricing as there is less activity to push the stock closer to fair value? … Is there still an opportunity here to buy. … Let’s examine ChromaDex’s valuation and outlook in more detail to determine if there’s still a bargain opportunity

Simply Wall St -

Volatility 101: Should ChromaDex Shares Have Dropped 38%?

ChromaDex isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. … Over five years, ChromaDex grew its revenue at 15% per year. … So now is probably an apt time to look closer at the stock, if you think it has potential.

Simply Wall St -

ChromaDex Corporation (NASDAQ:CDXC): Risks You Need To Consider Before Buying

In finance, Beta is a measure of volatility. … Every stock in the market is exposed to this volatility, which is linked to the fact that stocks prices are correlated in an efficient market. … Beta is a widely used metric to measure a stock's exposure to market risk (volatility).

Simply Wall St -

Who Are ChromaDex Corporation's (NASDAQ:CDXC) Major Shareholders?

Today, I will be analyzing ChromaDex Corporation’s (NASDAQ:CDXC) recent ownership structure, an important but not-so-popular subject among individual investors. … Ownership structure of a company has been found to affect share performance over time. … NasdaqCM:CDXC Ownership Summary July 17th 18

Simply Wall St -

ChromaDex Corporation's (NASDAQ:CDXC) Shift From Loss To Profit

The US$203.55m market-cap posted a loss in its most recent financial year of -US$16.53m and a latest trailing-twelve-month loss of -US$23.17m leading to an even wider gap between loss and breakeven. … In this article, I will touch on the expectations for CDXC’s growth and when analysts expect the company to become profitable … CDXC is bordering on breakeven, according to Life Sciences analysts.

Simply Wall St -

Should You Buy ChromaDex Corporation (NASDAQ:CDXC) Now?

ChromaDex Corporation (NASDAQ:CDXC), a life sciences company based in United States, saw significant share price volatility over the past couple of months on the NasdaqCM, rising to the highs of $5.53 and falling to the lows of $3.51. … The stock’s ratio of 3.58x is currently trading slightly above its industry peers’ ratio of 3.23x, which means if you buy ChromaDex today, you’d be paying a relatively reasonable price for it. … And if you believe ChromaDex should be trading in this range, then there isn’t really any room for the share price grow beyond what it’s currently trading.

Simply Wall St -

ChromaDex Corporation's (NASDAQ:CDXC) Path To Profitability

So, CDXC is predicted to breakeven approximately a couple of months from now! … What rate will CDXC have to grow year-on-year in order to breakeven on this date? … Next Steps: This article is not intended to be a comprehensive analysis on CDXC, so if you are interested in understanding the company at a deeper level, take a look at CDXC’s company page on Simply Wall St.

Simply Wall St -

Is ChromaDex Corporation's (CDXC) Balance Sheet A Threat To Its Future?

Check out our latest analysis for ChromaDex Does CDXC generate enough cash through operations? … During times of unfavourable events, CDXC could be required to liquidate some of its assets to meet these upcoming payments, as cash flow from operations is hindered. … Our analysis shows that CDXC is able to meet its upcoming commitments with its cash and other short-term assets, which lessens our concerns for the company's business operations should any unfavourable circumstances arise.

Simply Wall St -

CDXC Company Info

Description

ChromaDex Corporation operates as a nutraceutical company. The company offers Nicotinamide riboside (NIAGEN), a novel form of vitamin B3 for enhancing nicotinamide adenine dinucleotide (NAD) level used for healthy aging; and Immulina, a spirulina extract and compound, which is used for improving human immune function. It also provides reference standards and fine chemicals to conduct quality control of raw materials and finished products in dietary supplements, cosmetics, food and beverages, and pharmaceutical industries. In addition, the company offers a range of consulting services, including regulatory support, product development, risk management, and litigation support. The company markets and sells its products directly in the United States and Canada; and through international distributors. ChromaDex Corporation is based in Irvine, California.

Details
Name: ChromaDex Corporation
CDXC
Exchange: NasdaqCM
Founded:
$209,898,139
59,970,897
Website: http://www.chromadex.com
Address: ChromaDex Corporation
10900 Wilshire Boulevard,
Suite 650,
Irvine,
California, 90024,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CDXC Common Stock Nasdaq Capital Market US USD 23. Jun 2008
DB OCD1 Common Stock Deutsche Boerse AG DE EUR 23. Jun 2008
Number of employees
Current staff
Staff numbers
110
ChromaDex employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/07 03:32
End of day share price update: 2020/04/06 00:00
Last estimates confirmation: 2020/03/11
Last earnings filing: 2020/03/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.